Ben Wallwork practises intellectual property law, with an emphasis on pharmaceutical patent litigation. He has particular experience in proceedings under the Patented Medicines (Notice of Compliance) Regulations, as well as patent impeachment, infringement and damages actions. His litigation practice further includes matters pertaining to regulatory issues, trade-marks, copyright, trade secrets, and confidentiality, as well as disputes relating to Internet domains and social media.
Mr. Wallwork also advises clients on pharmaceutical regulatory and compliance matters, including market access, privacy, pricing, promotion, marketing and advertising, and anti-bribery and corruption.
Prior to joining our Toronto office, Mr. Wallwork worked in the intellectual property group at a Canadian national firm.
On October 30, 2016, Canadian and European Union (EU) leaders signed the Comprehensive Economic and Trade Agreement (CETA), capping a seven-year negotiation process. On October 31, 2016, the Canadian government tabled Bill C-30 (First Reading), which is intended to implement CETA into Canadian law..
November 02, 2016
Pfizer Canada Inc. (Pfizer) markets an extended release formulation of the drug venlafaxine hydrochloride in Canada under the name EFFEXOR XR®..
June 10, 2016